Richmond Brothers Inc. lifted its holdings in shares of DURECT Co. (NASDAQ:DRRX – Free Report) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,281,176 shares of the specialty pharmaceutical company’s stock after buying an additional 138,920 shares during the quarter. DURECT comprises 0.6% of Richmond Brothers Inc.’s investment portfolio, making the stock its 23rd biggest position. Richmond Brothers Inc. owned about 4.13% of DURECT worth $961,000 as of its most recent SEC filing.
Separately, Geode Capital Management LLC lifted its stake in shares of DURECT by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 14,658 shares in the last quarter. 28.03% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, StockNews.com began coverage on shares of DURECT in a report on Wednesday. They set a “sell” rating on the stock.
DURECT Price Performance
Shares of NASDAQ:DRRX opened at $0.80 on Wednesday. The company’s fifty day moving average price is $0.80 and its 200-day moving average price is $1.04. The firm has a market capitalization of $24.83 million, a price-to-earnings ratio of -1.31 and a beta of 0.91. DURECT Co. has a one year low of $0.70 and a one year high of $1.88.
DURECT Company Profile
DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.
Featured Articles
- Five stocks we like better than DURECT
- What is a Secondary Public Offering? What Investors Need to Know
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How to Invest in Blue Chip Stocks
- 3 Must-Own Stocks to Build Wealth This Decade
- What is Forex and How Does it Work?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.
